Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
BusinessWeek November 25, 2009 Arlene Weintraub	Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance.
BusinessWeek July 1, 2010 Doherty & Waters	Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand
The Motley Fool July 16, 2007 Brian Orelli	Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note.
The Motley Fool August 22, 2007 Brian Orelli	Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool March 30, 2004 Charly Travers	Genentech: Priced for Perfection Can Genentech's earnings growth keep up with its valuation? The launch of three new products in the last nine months has made Genentech a very popular, and expensive, company.
The Motley Fool March 12, 2009 Brian Orelli	2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders.
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool July 20, 2005 Stephen D. Simpson	Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
BusinessWeek October 1, 2007 Conrad Wilson	A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution.
HBS Working Knowledge August 30, 2004 Dyer, Kale & Singh	Alliance or Acquisition? Companies that use both alliances and acquisitions--rather than one or the other--may grow faster. Here's how to make the best strategic choice.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
The Motley Fool May 19, 2009 Alex Dumortier	Is This 14.4% Annualized Return Risk-Free? A merger arbitrage that looks relatively low-risk.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool January 11, 2005 W.D. Crotty	Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced.
Chemistry World March 13, 2009 Sarah Houlton	Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge.
BusinessWeek October 30, 2008	Four New Pharmaceutical Chief Executives Speak Out The CEOs of Pfizer, Roche, Eli Lilly, and Bristol-Myers Squibb address topics from dealmaking to the pharmaceutical industry's image problems.
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool January 20, 2009 Anders Bylund	3 Stocks That Missed the Mark These companies overpromised and under delivered: Alcoa... Genentech... Bank of America...
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool January 16, 2009 Brian Orelli	Sealed Lips Don't Sink Ships At the JPMorgan health care conference, there's updates aplenty, but not for the most interesting stories.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool July 12, 2007 Brian Lawler	Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
The Motley Fool August 1, 2007 Billy Fisher	Overseas Growth Sparks OSI's Earnings OSI Pharmaceuticals continues to prosper, and it has Tarceva to thank. But what happens when Tarceva becomes obsolete around 2009? Investors, take note.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool October 8, 2004 Charly Travers	Genentech's Wealth Transfer Program Genentech's stock is even more expensive than you think.
The Motley Fool October 3, 2008 David Lee Smith	Inching Toward That Massive Mining Marriage BHP appears to be slowly approaching its courtship with Rio Tinto.
The Motley Fool February 7, 2008 David Lee Smith	BHP Billiton Eyes Its Prey Along with releasing solid results, BHP Billiton also ups the ante for rival Rio Tinto.
The Motley Fool December 4, 2008 Brian Orelli	Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field.
The Motley Fool December 12, 2005 Shannon Zimmerman	Genentech: Good Company, Bad Investment Stock valuations in the biotech industry are expensive in general, but on a trailing-12-month basis, Genentech's price-to-earnings, price-to-book, price-to-sales, and price-to-cash flow figures all dwarf those of the broader market. If the price isn't right, buyer beware.
InternetNews June 29, 2009 David Needle	Facebook Fills CFO Spot - Does IPO Loom? Facebook hires a veteran of Genentech to fill its chief financial officer position.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
The Motley Fool November 12, 2008 David Lee Smith	This Miner Chase Could Make Money for You Australia's BHP Billiton's lengthy effort to acquire its London-based competitor, Rio Tinto, may be about to clear its final hurdle.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
The Motley Fool July 9, 2007 Rich Smith	Before the Call: Gauging Genentech Investors, don't focus on just this quarter. What's the big picture look like for the drug maker? Many investors seem willing to wait around for this stock.
The Motley Fool August 15, 2006 Jim Mueller	Sonic Goes Dutch at the Drive-In A modified Dutch tender offer will reduce outstanding shares and increase value to shareholders of the drive-in burger purveyor.
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.